The role of interleukin-2 in the treatment of cancer patients [Paperback]

Recombinant human interleukin-2 became available for clinical use in the mid 1980s. Recent years have seen an enormous amount of clinical research with this cytokine and interleukin-2 has now been registered for use in a number of European countries for the treatment of metastatic renal cell carcinoma. This book is designed to provide the clinical oncologist wishing to use interleukin-2 with a basic background concerning the biology of the agent, a discussion concerning practical aspects, of its clinical use including management of toxicity and an overview of the clinical results together with a description of how this internesting cytokine might be developed in the future.Recombinant human interleukin-2 became available for clinical use in the mid 1980s. Recent years have seen an enormous amount of clinical research with this cytokine and interleukin-2 has now been registered for use in a number of European countries for the treatment of metastatic renal cell carcinoma. This book is designed to provide the clinical oncologist wishing to use interleukin-2 with a basic background concerning the biology of the agent, a discussion concerning practical aspects, of its clinical use including management of toxicity and an overview of the clinical results together with a description of how this internesting cytokine might be developed in the future.Preface. 1. Introduction; J. Wagstaff. 2. Interleukin-2 as a single Agent: Dose, Scheduling and Optimum Immunomodularity Dose; L.M. Jost, R.A. Stahel. 3. Interleukin-2 and Lymphokine Activated Killer (LAK) Cells; S. Negrier, T.P. Philip. 4. Interleukin-2 Toxicity: Mechanisms and Management; J.W. Baars. 5. Interleukin-2: Biology and Immunology; G. Parmiani, C. Gambacorti-Passerini. 6. Interleukin-2 and Tumour Eradication by Cytotoxic T Lymphocytes; C.J.M. Melief, W.M. Kast. 7. Combination Treatment with Interleukin-2 and Chemotherapeutic Agents; A. von RohlÃ;